ACNS1221 : A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age

ID Number 80-0066-00221

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)
Hematology and Medical Oncology


Several past studies in Europe have shown that infants with Desmoplastic Medulloblastoma had very good treatment outcomes when treated with the usual chemotherapy drugs; (etoposide, cyclophosphamide, cisplatin and vincristine) in addition to the use of a drug called methtrexate given in high doses into the veins, and into the fluid-containing spaces in the brain (called intraventricular spaces).

In this study, researchers want to see if giving subjects with Desmoplastic Medulloblastoma this modified therapy will maintain good survival outcomes with little or no side effects.

Contact Information
Dr Birte Wistinghausen
(212) 824-7309

Recruiting Patients: Yes